Key points are not available for this paper at this time.
At least in the short-term, the clinical practice of the specialised Italian centres taking part in the study confirms that switching patients to a biologic drug produces an incremental cost-effectiveness ratio comparable with the values predicted by the HTA bodies.
Spandonaro et al. (Mon,) studied this question.